SRC and breast cancer: The docking study revealed diosgenin to interact with active site residues of three potential targets involved in breast cancer via IGF1R, MDM2, and SRC. Diosgenin formed stable intermolecular interactions throughout 150 ns MD simulation revealing them as the best lead.